Inventor · disambiguated record
Ewelina Morawa
Also filed as: MORAWA EWELINA
2 granted patents·8 pending applications·1 citations·filing 2018–2024
35Inventor score
Top patents by PatentIndex Score
10 records- 0184US11389481B2Allogeneic cell therapy of B cell malignancies using genetically engineered T cells targeting CD19CRISPR THERAPEUTICS AG·Filed 2021·Granted Jul 19, 2022·1 cites·20 claims
- 0272US2025041349A1CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses ThereofVERTEX PHARMA·Filed 2024·Application pending·0 cites
- 0358US12161674B2CRISPR-CAS9 modified CD34+ human hematopoietic stem and progenitor cells and uses thereofVERTEX PHARMA·Filed 2018·Granted Dec 10, 2024·0 cites·16 claims
- 0457US2024115703A1Genetically engineered anti-cd19 car-t cells for use in treating b-cell malignanciesCRISPR THERAPEUTICS AG·Filed 2023·Application pending·0 cites
- 0556US2022249558A1Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19CRISPR THERAPEUTICS AG·Filed 2020·Application pending·0 cites
- 0656US2022202859A1Cancer treatment using cd38 inhibitor and/or lenalidomide and t-cells expressing a chimeric antigen receptorCRISPR THERAPEUTICS AG·Filed 2021·Application pending·0 cites
- 0754US2022008473A1Use of chimeric antigen receptor t cells and nk cell inhibitors for treating cancerCRISPR THERAPEUTICS AG·Filed 2021·Application pending·0 cites
- 0854US2022118019A1Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19CRISPR THERAPEUTICS AG·Filed 2021·Application pending·0 cites
- 0952US2022023344A1Allogeneic cell therapy of acute lymphoblastic leukemia using genetically engineered t cells targeting cd19CRISPR THERAPEUTICS AG·Filed 2021·Application pending·0 cites
- 1051US2023220059A1Genetically engineered t cells expressing bcma-specific chimeric antigen receptors and uses thereof in cancer therapyCRISPR THERAPEUTICS AG·Filed 2021·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Ewelina Morawa files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →